Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

N-acetilglucosamina oral en la enfermedad de Crohn (NAGIC)

3 de noviembre de 2026 actualizado por: Johns Hopkins University

El Estudio NAGIC-OL: Estudio abierto de N-acetilglucosamina oral en la enfermedad de Crohn ileal

Protein glycosylation is a critical post-translational modification that regulates protein trafficking and protein-protein interactions impacting a host of physiological processes. There is a growing appreciation of glycosylation defects in chronic human diseases, including Crohns disease. Crohns disease (CD), and the related condition of ulcerative colitis, are chronic inflammatory bowel diseases (IBD) that impact 3.1 million Americans. While the development of medications has revolutionized care of CD patients, clinical remission is only achieved in ~40% of patients a therapeutic ceiling that has not changed in 20 years. These data underscore the need for new CD treatment strategies. The investigators are focused on understanding the role of defective N-glycosylation in CD, as an innovative strategy to identify and develop new therapeutics. Depending on ancestral background, 7-25% of CD patients carry a pathogenic, missense mutation in the manganese (Mn) transporter ZIP8 (rs13107325; ZIP8 A391T). ZIP8 regulates systemic Mn homeostasis with ZIP8 391-Thr causing a relative Mn insufficiency. Mn is a required metal cofactor for enzymes regulating key cellular processes, like N-glycosylation. In the gut, protein N-glycosylation plays key roles in host-pathogen interactions, inflammation, and cell-cell interactions. The investigator's central hypothesis is that in patients carrying ZIP8 391-Thr - CD is exacerbated by aberrant N-glycosylation and that this defect can be targeted by specific, safe therapy. Supporting this hypothesis, Mn levels are reduced (~15%) in ZIP8 391-Thr allele carriers and this is associated with a decrease in complex N-glycan branching in plasma. Further, the investigators uncovered a microbiota signature in the ileal mucosa that implicated altered bile acid homeostasis in ZIP8 391-Thr carriers. To better understand CD in ZIP8 391 carriers, the investigators generated a knock-in mouse model of ZIP8 391-Thr (Zip8393T/393T). Like patient data, the investigators observe reduced branching of N-glycans and disrupted bile acid homeostasis in the Zip8393T/393T mice. Promising human trials have shown that defects in N-glycan branching can be safely restored by raising levels of the rate-limiting metabolite UDP-N-acetylglucosamine (GlcNAc) via supplementation with free GlcNAc. The investigator's preliminary data in Zip8393T/393T mice have demonstrated that GlcNAc supplementation restores N-glycan branching deficits, rescues the defect in bile acid homeostasis, and ameliorates colitis susceptibility. Thus, the objective of the proposed research is to test a safe and effective therapy for patients carrying ZIP8 391-Thr and others who may have underlying changes in N-glycosylation.

The investigators will perform a multi-center, randomized, double-blind, placebo-controlled cross-over study to test the safety and tolerability of oral GlcNAc as a proof-of-concept study. The investigators will use two cohorts stratified by ZIP8 391-Thr genotype status (carriers and non-carriers, n= 20 participants in each cohort, total= 40 participants).

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

While many new medications improved care for patients with Crohn's disease, clinical remission is only achieved in ~40% of patients - a therapeutic ceiling that has not changed in 20 years. These data underscore the need for new treatment strategies and (the investigators hypothesize) greater focus on personalized medicine using factors like genetics.

This study is a clinical trial of oral N-acetylglucosamine (GlcNAc) in patients with Crohn's disease. The investigators are aiming for approximately half of the participants to carry a genetic variant in a gene called ZIP8. ZIP8 regulates levels of manganese and the variant lowers levels of manganese; manganese levels may also be reduced for reasons other than just ZIP8 genetics - including variation in dietary intake, water sources, and inflammation - therefore, the investigators are also enrolling participants who do not have the ZIP8 variant. Manganese is a nutrient absorbed from food that is required for glycosylation, but direct supplementation of excess manganese may carry risk of neurologic side effects. An alternative approach is to supplement with GlcNAc, the critical building block of glycosylation that regulates intestinal health and inflammation. GlcNAc is preferred given its positive safety profile and prior small studies in patients with inflammatory bowel disease that showed promising results.

Key study information:

  • The investigators will check if the participant carries the ZIP8 variant at study enrollment. The participants can choose to be informed of ZIP8 genetics.

  • This is a randomized, double-blind, placebo-controlled, cross-over study. This study design provides the most power to determine if there is a beneficial effect of GlcNAc.

  • This means the participant will receive the study drug (GlcNAc), but will also have a period of placebo. The sequence in which the participant receives the GlcNAc or placebo is randomized. The study is blinded, meaning that the participant and the investigator will not know if the participant is receiving active drug or placebo unless there are safety concerns.

  • GlcNAc or placebo is provided to the participant as a powder that the participant will mix in a small amount of water 3 times per day.

  • GlcNAc is a naturally-occurring substance found in nature and tastes sweet when mixed with water.

  • The study runs for 18 weeks. There are brief, weekly check-ins and 7-8 in-person visits.

  • Participants will be asked to provide blood, stool, and saliva samples for a total of 7-8 times.

  • If it is possible at the participant's site, intestinal ultrasounds will be performed over the course of the study.

    • Participants will be paid to participate in the study. There are no direct costs to the participants.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Joanna MP Melia, MD
  • Número de teléfono: 410-502-1559
  • Correo electrónico: jpeloqu2@jhmi.edu

Ubicaciones de estudio

    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21205
        • Johns Hopkins University School of Medicine
        • Contacto:
          • Joanna MP Melia, MD
          • Número de teléfono: 410-502-1559
          • Correo electrónico: jpeloqu2@jhmi.edu
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age 18 and 80 years of age
  2. Diagnosis of CD involving ileum (L1) or ileocolonic disease (L3) of any disease behavior
  3. On stable dosing of any CD therapy for >/= 8 weeks (inclusive of biologics, small molecules, immunomodulators)
  4. CDAI <450
  5. Willing to undergo genetic testing for ZIP8 genotype
  6. No steroids within the past 4 weeks
  7. No antibiotics within the past 2 weeks
  8. Willing to provide informed consent
  9. Willing to participate in all at-home and clinic-based follow-up
  10. Willing to provide most recent endoscopy and imaging results; when possible, access to prior pathology specimens
  11. Willing to use all forms of "highly effective" contraception throughout the study period and for 30 days after the last dose of study drug (all subjects of child-bearing potential)

Exclusion criteria

  1. Have taken GlcNAc or glucosamine in the previous 3 months
  2. Allergy to shellfish
  3. Severely-active CD defined as CDAI >450 AND/OR
  4. Simple Endoscopic Score for Crohn's Disease (SES-CD) score >/= 16 (or >/= 8 for isolated ileitis) on colonoscopy within 8 weeks of screening, if available
  5. Steroids within the past 4 weeks
  6. Antibiotics within the past 2 weeks
  7. Stricture with high-grade obstruction, significant fistulizing disease, presence of intra-abdominal or perianal abscess, perforation, or fulminant colitis requiring imminent surgical management
  8. Surgery within 12 weeks
  9. Recent initiation or escalation of immunosuppressive therapy (<8 weeks)
  10. Any clinically significant abnormalities on routine clinical labs, including unexplained white blood cells (WBC) >16,000, hemoglobin <7, AST/ALT >2x ULN, alkaline phosphatase >2x ULN, eGFR <60, ferritin <30 ng/ml2
  11. History of type 1 diabetes, inadequately controlled type 2 diabetes (HbA1c>6.5%), type 2 diabetes on insulin
  12. History of peripheral vascular disease, coronary artery disease, stroke, transient ischemic attack
  13. History of cancer
  14. History of organ transplant
  15. History of bleeding disorder
  16. History of chronic respiratory disorder, including asthma
  17. History of chronic renal failure
  18. History of chronic liver disease, including primary sclerosing cholangitis
  19. History of seizure disorder
  20. Pregnant, less than 6 months postpartum, breastfeeding, or attempting to conceive

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Participants with Crohn's disease and carry ZIP8 391-Thr (heterozygous or homozygous carriers)

N-acetylglucosamine

This is a placebo-controlled, cross-over design. The sequence in which the participant receives the GlcNAc or placebo is randomized. Participants will take GlcNAc 2 grams three times daily or placebo (glucose 2 grams three times daily) for 6 weeks. There will then be a 3 week washout period and then cross-over to GlcNAc or placebo for 6 weeks. Participants will be followed for 3 weeks off all drug/placebo to complete the study at week 18.

Experimental: Participants with Crohn's disease who do not carry ZIP8 391-Thr

N-acetylglucosamine

This is a placebo-controlled, cross-over design. The sequence in which the participant receives the GlcNAc or placebo is randomized. Participants will take GlcNAc 2 grams three times daily or placebo (glucose 2 grams three times daily) for 6 weeks. There will then be a 3 week washout period and then cross-over to GlcNAc or placebo for 6 weeks. Participants will be followed for 3 weeks off all drug/placebo to complete the study at week 18.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and tolerability: Number of Crohn's disease exacerbations
Periodo de tiempo: Weeks 0-6, Weeks 6-9, Weeks 9-15, Weeks 15-18

Safety and tolerability will be defined as freedom from Crohn's disease (CD) disease exacerbation. Number of CD exacerbations will be one composite outcome with exacerbation of CD activity defined as the occurrence of ANY of the following during each treatment phase:

i. Crohn's disease activity index (CDAI) score (patient reported measure) change of >100 points, ii. initiation or change of CD therapy due to symptom worsening, iii. need for steroids related to CD disease activity, iv. CD-associated hospitalization, v. CD-associated surgery, vi. severe adverse events (CTCAE grade 3-5, attributed to CD disease activity, e.g. life-threatening perforation or sepsis)

Weeks 0-6, Weeks 6-9, Weeks 9-15, Weeks 15-18

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical response as assessed by CDAI score
Periodo de tiempo: Week 6, week 15 for each treatment phase (GlcNAc and placebo)

Patient reported disease activity index: CDAI score range from 0 to 600; scores <150 define remission, 150 to 219 mild activity, 220 to 450 moderate activity, and greater than 450 severe activity.

Clinical response will be defined as a ≥70 point reduction in CDAI score from baseline by the end of the six-week treatment period stratified by disease activity at week 0.

Week 6, week 15 for each treatment phase (GlcNAc and placebo)
Clinical response as assessed by mean change in CDAI score
Periodo de tiempo: Week 6, week 15 for each treatment phase (GlcNAc and placebo).

Patient reported disease activity index: CDAI score range from 0 to 600; scores <150 define remission, 150 to 219 mild activity, 220 to 450 moderate activity, and greater than 450 severe activity. Within-participant change from baseline in CDAI score stratified by disease activity at week 0.

Week 6, week 15 for each treatment phase (GlcNAc and placebo).
Clinical remission as assessed by CDAI score
Periodo de tiempo: Week 6, week 15 for each treatment phase (GlcNAc and placebo).

Patient reported disease activity index: CDAI score range from 0 to 600; scores <150 define remission, 150 to 219 mild activity, 220 to 450 moderate activity, and greater than 450 severe activity. Clinical remission will be defined as a CDAI score of <150 at the end of the six-week treatment period stratified by disease activity at week 0.

Week 6, week 15 for each treatment phase (GlcNAc and placebo).
Change in serum N-glycome
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of glycosylation Serum N-glycome (%): Change in Serum N-glycome from baseline to follow-up

Week 0, 6, 9, 15, 18
Change in saliva N-glycome
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of glycosylation: Change in saliva N-glycome (%) from baseline to follow-up.

Week 0, 6, 9, 15, 18
Mean change in serum UDP-GlcNAc
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of glycosylation: Serum UDP-GlcNAc (uM). Mean change in serum UDP-GlcNAc from baseline to follow-up.

Week 0, 6, 9, 15, 18
Change in T cell N-glycan branching
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of glycosylation: Change in T cell N-glycan branching (%) from baseline to follow-up

Week 0, 6, 9, 15, 18
Change in T cell activity/responsiveness
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of glycosylation: Change in T cell activity/responsiveness (%) from baseline to follow-up

Week 0, 6, 9, 15, 18
Change in fecal mucins
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of glycosylation: Change in fecal mucins (%) from baseline to follow-up

Week 0, 6, 9, 15, 18
Mean change in fecal calprotectin
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of inflammation. Mean change in fecal calprotectin (%) from baseline to follow-up

Week 0, 6, 9, 15, 18
Mean change in serum C-Reactive Protein (CRP)
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of inflammation: CRP (ng/ml) from baseline to follow-up

Week 0, 6, 9, 15, 18
Change in panel-based blood inflammatory cytokines
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of inflammation: Change in panel-based blood inflammatory cytokines (pg/ml) measures from baseline to follow-up.

Week 0, 6, 9, 15, 18
Change in marker of bile acid homeostasis (FGF19)
Periodo de tiempo: Week 0, 6, 9, 15, 18

FGF19 is a circulating protein that is a marker of bile acid homeostasis.

Week 0, 6, 9, 15, 18
Mean change in sCD14
Periodo de tiempo: Week 0, 6, 9, 15, 18

Measure of intestinal permeability sCD14 (pg/ml). Mean change in sCD14 from baseline to follow-up.

Week 0, 6, 9, 15, 18
Mean Change in FACIT-Fatigue Patient-reported measure (Fatigue)
Periodo de tiempo: Week 0, 6, 9, 15, 18

Patient-reported measure. Mean change in FACIT-Fatigue scores from baseline (Week 0) to final intervention (Week 13), with a clinical significant threshold set at >/= 4 points. Score ranges from 0 to 52 with higher scores indicating worse fatigue.

Week 0, 6, 9, 15, 18
Mean Change in Simple Ultrasound Activity (SUS-CD) Score Disease activity measured by intestinal ultrasound
Periodo de tiempo: Week 0, 6, 9, 15, 18

Disease activity: Mean change in simple ultrasound activity score (includes bowel wall thickness and color Doppler signals) for Crohn's disease at Week 13. Score range 0-5 with 0-1 indicating normal or very mild disease; 2-3 moderate disease; 4-5 severe active disease.

Week 0, 6, 9, 15, 18

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Joanna Melia, MD, Johns Hopkins University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

5 de enero de 2027

Finalización primaria (Estimado)

31 de julio de 2028

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

29 de octubre de 2025

Primero enviado que cumplió con los criterios de control de calidad

5 de noviembre de 2025

Publicado por primera vez (Actual)

10 de noviembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB00533883
  • 2604-09127 (Otro número de subvención/financiamiento: Leona M. & Harry B. Helmsley Charitable Trust)
  • R01DK141870 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Individual participant data (IPD) (data collected for each person, including demographics, Crohn's disease history, lab results, adverse events) will be shared after publication of results for research collaborations. IPD will be shared as a deidentified dataset with no protected health information (PHI) as per Institutional Review Board (IRB) regulations. Data sharing agreement will be required.

Marco de tiempo para compartir IPD

Data will be available approximately 18 months after trial completion (after publication of results) and available for at least 5 years.

Criterios de acceso compartido de IPD

Individuals interested in access the IPD and supporting information will be able to access data collected for each person, including demographics, Crohn's disease history, lab results, adverse events, after data use agreement is signed by relevant parties.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir